CTLA-4 Blockade With MDX-010 to Induce Graft-Versus-Malignancy Effects Following Allogeneic Hematopoietic Stem Cell Transplantation.
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2013
At a glance
- Drugs Ipilimumab (Primary)
- Indications Cancer; Graft-versus-host disease
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 01 Sep 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov record.
- 01 May 2008 Status changed to suspended as reported by ClinicalTrials.gov